Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human MAP kinase 11 / p38 beta, active, 10 µg  

Recombinant human MAP kinase 11 / p38 beta, active, 10 µg

Recombinant human mitogen-activated protein kinase 11 / p38 beta / SAPK2, active enzyme

Alternate names: recombinant human p38 protein kinase, SAPK2, Stress-activated protein kinase 2, MAPK11, mitogen-activated protein kinase 11, p38 β

More details

PK-SAPK2B-A010

Availability: within 3 days

295,00 €

Background: The p38 MAPK (mitogen-activated protein kinase) pathway contains protein kinases which engage in respond to various extracellular stimuli an intracellular signalling cascade, coordinating the activation of gene transcription, protein synthesis, cell cycle machinery, cell death, and differentiation. The different p38 MAPK family members (p38α, p38β, p38γ, p38δ)  encoded by different genes show an approximately 60% identical in their amino acid sequence but have different tissue expression patterns. p38 MAPKs being activated by dual phosphorylation of the Thr-Gly-Tyr in the activation loop sequence by MKKs/MAP2Ks (MKK6 and MKK3). Down-regulation of p38 MAPK is achieved for instance by Wip1, a phosphatase of the PP2C family that can be transcriptionally up-regulated by p53 or by MKPs, a family of dual-specificity protein phosphatases. Upon activation p38 MAP kinases can phosphorylate substrates on Ser-Pro or Thr-Pro motifs on MSK1 and 2, which directly phosphorylate the transcription factors CREB, ATF1, or cytosolic proteins such as phospholipase A2, Bcl-2 family proteins and cyclins. Because of the important role of p38α in inflammatory diseases it is also an interesting pharmaceutical target. Based on SB203580, one of the first discovered p38α inhibitors structurally diverse p38α and p38β inhibitors have been developed with both enhanced potency and specificity.

Human p38b/SAPK2beta, recombinantly expressed in E. coli., full lenght protein, untagged, activated with MKK6 SDTD

Protein: Recombinant, human p38-beta, full length, N-terminally fused to HIS6
Theoretical MW : 41.5 kDa
Expression system: E.coli
Purification: affinity purification using immobilized metal affinity chromatography (IMAC) resin charged with cobalt
Activation: activated with GST-MKK6, mutationally acivated : S207D/T211D, separated from p38-beta using glutathione agarose
Storage buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM DTT, 20% glycerol
Purity: >99 %
Protein concentration: 0.45 mg/ml (Bradford method using BSA as standard protein)
Method for determination of specific activity: luminescent ADP detection assay, ADP- GloTM
Specific activity: 333,000 U*/mg

Entrez Gene ID: 5600
UniProtKB: Q15759

Ordering information: shipped on dry ice

BIAFFIN SERVICES:

Use the p38 MAPK - SPR Binding Assay of BIAFFIN for comprehensive kinetic characterization of your small molecule kinase inhibitors. 

P38b_SB203580.png 

Figure: Real-time kinetic analysis of kinase inhibitor SB203580 binding to p38β using surface plasmon resonance.

We provide our Kinascreen services to kinetically characterize small molecule kinase inhibitors for all p38 isoforms (p38α, p38β, p38γ and p38δ) in their phosphorylated (activated) and unphosphorylated (non-activated) state. 

Please contact our application specialists to obtain more information and an individual quote tailored to your specific needs. 

Product specific literature references:

Cuadrado A, Nebreda AR.  (2010) “Mechanisms and functions of p38 MAPK signalling.” Biochem J. 1;429(3):403-17.

Kyriakis JM, Avruch J. (2001) „Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.“ Physiol Rev.81(2):807-69.

Roux PP, Blenis J.,(2004) “ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.” Microbiol Mol Biol Rev. 68(2):320-44.

Shin J, Park B, Ahn K eta al. (2004) "Promyelocytic leukemia is a direct inhibitor of SAPK2/p38 mitogen-activated protein kinase" J Biol Chem. 279(39):40994-1003

Saklatvala J (2004) "The p38 MAP kinase pathway as a therapeutic target in inflammatory disease" Curr Opin Pharmacol. 4(4):372-7

The following products could also be interesting for you: